C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an update.
C-RAD AB reported a solid first quarter in 2025, with a 5% increase in order intake and a slight revenue growth of 1% despite challenging market conditions. The company’s EBIT was impacted by unrealized currency effects, but the underlying profit remained strong. C-RAD continues to focus on strategic priorities, such as increasing market share, investing in product innovation, and expanding its service business. The company achieved significant growth in the service sector, particularly in EMEA and APAC, and secured important contracts in the US, UK, and other regions. Despite uncertainties in the market due to geopolitical and tariff issues, C-RAD remains committed to its long-term goals of achieving profitable growth and enhancing its product offerings.
More about C-Rad AB Class B
C-RAD AB is a company operating in the medical technology industry, focusing on providing advanced solutions for radiation therapy. The company specializes in products and services that enhance the precision and effectiveness of radiotherapy treatments, with a strong emphasis on Surface Guided Radiation Therapy (SGRT) systems. C-RAD is committed to expanding its market presence across various regions, including the Americas, EMEA, and APAC, and aims to strengthen its service business to foster long-term customer relationships.
Average Trading Volume: 46,979
Current Market Cap: SEK1.03B
For detailed information about CRAD.B stock, go to TipRanks’ Stock Analysis page.